Literature DB >> 6194706

Role of phospholipase A2 activation in histamine release from human basophils.

Y Morita, N Aida, T Miyamoto.   

Abstract

The present experiments were undertaken to investigate the role of phospholipase A2 (PLA2) activation in histamine release from human basophils. A PLA2 inhibitor, P-bromophenacyl bromide (BPB), inhibited IgE-mediated anti-IgE-induced histamine release from human basophils with a concentration of drug required to produce 50% inhibition (IC50) of 1.5 x 10(-6) M when leukocytes were preincubated with this agent for 15 min. Histamine release induced by calcium ionophore A23187 and formyl-L-methionyl-L-leucyl-L-phenylalanine was also blocked by BPB with IC50 of 4.1 x 10(-6) M, and 3.5 x 10(-6) M, respectively. A PLA2 activator, 12-0-tetradecanoylphorbol-13-acetate (TPA) caused basophil histamine release with a dose-dependent fashion. BPB inhibited TPA-induced histamine release (IC50: 2.5 x 10(-6) M). However, another PLA2 activator, melittin, and PLA2 did not release histamine through non-cytotoxic mechanisms. Collectively, these results suggest that PLA2 activation plays a central role in histamine release from human basophils via generation of lysophosphatidylcholine or products of the lipoxygenase pathway of arachidonic acid metabolism.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6194706     DOI: 10.1111/j.1398-9995.1983.tb05084.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  3 in total

1.  Effects of mepacrine and p-bromophenacyl bromide on anti-IgE and phospholipase A2-induced histamine release from human basophils.

Authors:  J B Toll; R G Andersson
Journal:  Agents Actions       Date:  1986-08

Review 2.  Basophil histamine release. Assays and interpretation.

Authors:  I B Haydik; W S Ma
Journal:  Clin Rev Allergy       Date:  1988

Review 3.  Histamine, histamine receptors, and neuropathic pain relief.

Authors:  Ilona Obara; Vsevolod Telezhkin; Ibrahim Alrashdi; Paul L Chazot
Journal:  Br J Pharmacol       Date:  2019-06-07       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.